All Brands Owned by Piramal Pharma Limited

What does Piramal Pharma own?
Piramal Pharma owns three business divisions: Piramal Pharma Solutions (CDMO services), Piramal Critical Care (hospital generics and inhalational anesthetics), and the Consumer Healthcare Division (OTC products in India). Its consumer brands include Lacto Calamine, i-pill, Saridon, Littles, and Naturolax. The company operates 17 manufacturing facilities across India, the United States, the United Kingdom, Canada, and Germany.

Is Piramal Pharma publicly traded?
Yes, Piramal Pharma is listed on the National Stock Exchange of India (NSE: PPLPHARMA) and the Bombay Stock Exchange (BSE: 543635). The company was demerged from Piramal Enterprises Limited and listed as a separate entity on October 19, 2022. Shares are held by institutional investors, the Piramal family, Carlyle Group, and public shareholders.

Who founded Piramal Pharma?
Piramal Pharma's origins trace to 1988, when the Piramal Group, led by Ajay Piramal, acquired Nicholas Laboratories India Limited. This acquisition marked the group's entry into the pharmaceutical industry. The modern Piramal Pharma Limited was created through a demerger from Piramal Enterprises in 2022. Ajay Piramal serves as Chairman, and his daughter Nandini Piramal serves as Executive Director.

Where is Piramal Pharma headquartered?
Piramal Pharma is headquartered in Mumbai, Maharashtra, India. The company's corporate offices are in the Piramal Tower in Lower Parel, Mumbai. The company was incorporated in India and is subject to Indian corporate law and regulations.

How many brands does Piramal Pharma own?
Piramal Pharma owns three business division brands (Piramal Pharma Solutions, Piramal Critical Care, and Piramal Consumer Healthcare) and approximately 7 consumer healthcare product brands sold in India. The consumer brands include Lacto Calamine, i-pill, Saridon, Littles, and Naturolax. See the full brand index for the complete list.

Who owns Piramal Pharma?
Piramal Pharma is controlled by the Piramal Group, led by Ajay Piramal and his family, which holds the majority of shares through Piramal Enterprises Limited and other group entities. The Carlyle Group holds a significant minority stake of approximately 15%, acquired through a $490 million investment in 2020. The remainder is held by institutional and public shareholders.

What is Piramal Pharma's revenue?
Piramal Pharma reported revenue of INR 82.1 billion for FY2025 (ending March 2025). The CDMO segment contributed approximately INR 49 billion, critical care approximately INR 20 billion, and consumer healthcare approximately INR 13 billion. The company has been investing in capacity expansion at its CDMO facilities to capture growth in HPAPIs and antibody-drug conjugates.

What is Piramal Pharma Solutions?
Piramal Pharma Solutions is the company's CDMO business division, providing integrated contract development and manufacturing services to global pharmaceutical companies. It offers services across the drug development lifecycle, from API synthesis to commercial manufacturing, with expertise in HPAPIs, sterile injectables, and antibody-drug conjugates. The division operates facilities in India, the United States, the United Kingdom, Canada, and Germany.